A total of 60 patients with the clinical diagnosis of BPH were monitored in this study; all were treated with tamsulosin 0.4 mg daily. The mean follow-up time was 3.97 ± 1.48 months (ranging from 1.5 to 7 months). Of 60 evaluated patients, 23 (38.3%) received finasteride 5 mg daily, concurrently. During the follow-up period, 10 patients (16.7%) underwent open prostatectomy or transurethral resection of the prostate (TURP).
The mean QoL (bother) scores before the treatment were 1.88 ± 0.88, 2.23 ± 1.09, and 2.95 ± 0.89 for the IPP grades 1, 2, and 3, respectively, indicating a statistically significant difference between the three groups (P = 0.001). Meanwhile, the mean QoL (bother) scores after the medical intervention were 1.76 ± 1.01, 2.08 ± 1.04, and 2.73 ± 1.35, respectively, for grades 1, 2, and 3, which again showed a significant difference (P = 0.020) (
Table 1). According to Pearson correlation coefficient, there was a significant direct correlation between IPP and Qol (bother) scores either before (correlation coefficient = 0.459, P < 0.001) or after the intervention (cc = 0.353, P = 0.006). In general, the QoL decreased significantly with increasing the IPP score (
Table 2).
| Grade 1 | Grade 2 | Grade 3 | P-Value |
|---|
| Qol | | | | |
| Pre-treatment | 1.88 ± 0.88 | 2.23 ± 1.09 | 2.95 ± 0.89 | 0.001 |
| Post-treatment | 1.76 ± 1.01 | 2.08 ± 1.04 | 2.73 ± 1.35 | 0.020 |
| IPSS | | | | |
| Pre-treatment | 10.88 ± 5.83 | 12.62 ± 5.04 | 16.36 ± 5.91 | 0.006 |
| Post-treatment | 11.08 ± 4.98 | 11.54 ± 4.14 | 17.27 ± 8.21 | 0.003 |
| PV | | | | |
| Pre-treatment | 36.68 ± 16.31 | 34.54 ± 8.64 | 68.18 ± 32.99 | < 0.001 |
| PVR | | | | |
| Pre-treatment | 31.20 ± 36.78 | 39.31 ± 40.38 | 69.14 ± 81.05 | 0.038 |
| | | | |
| Post-treatment | 21.68 ± 21.71 | 27.00 ± 26.70 | 61.77 ± 59.89 | 0.004 |
| PSA | | | | |
| Pre-treatment | 1.43 ± 0.80 | 1.32 ± 0.68 | 2.79 ± 0.89 | < 0.001 |
| Qmax | | | | |
| Pre-treatment | 16.21 ± 4.59 | 12.25 ± 1.50 | 11.17 ± 3.09 | 0.002 |
| Post-treatment | 18.07 ± 5.17 | 13.75 ± 2.99 | 9.83 ± 3.42 | 0.001 |
| Index | Correlation Coefficient | P-Value |
|---|
| Qol | | |
| Pre-treatment | 0.459 | < 0.001 |
| Post-treatment | 0.353 | 0.006 |
| IPSS | | |
| Pre-treatment | 0.397 | 0.002 |
| Post-treatment | 0.401 | 0.001 |
| PV | | |
| Pre-treatment | 0.504 | 0.001 |
| PVR | | |
| Pre-treatment | 0.293 | 0.029 |
| Post-treatment | 0.399 | 0.002 |
| PSA | | |
| Pre-treatment | 0.566 | < 0.001 |
| Qmax | | |
| Pre-treatment | -0.552 | < 0.001 |
| Post-treatment | -0.695 | < 0.001 |
The mean IPSS scores of patients, before the treatment, for grade 1, 2, and 3 subgroups were 10.88 ± 5.83, 12.62 ± 5.04%, and 16.36 ± 5.91, respectively. In other words, as the IPP increased, the IPSS score also increased (P = 0.006). After providing the medical intervention, the mean IPSS scores were 11.08 ± 4.98, 11.54 ± 4.14, and 17.27 ± 8.21, respectively. (P = 0.003). According to the Pearson correlation coefficient, there was a significant direct correlation between the IPP and IPSS scores, either before (cc = 0.397, P = 0.002) or after the treatment (cc = 0.40, P = 0.001).
Regarding the relationship between the IPP and PV indices (before treatment), mean PV for IPP subgroup grades of 1, 2, and 3 were 36.68 ± 16.31, 34.54 ± 8.64, and 68.18 ± 32.99, respectively. In this regard, the grade 3 patients with IPP > 10 mm had significantly higher PV than the other two subgroups (P < 0.001). There was a significant direct correlation between IPP and PV indices (cc = 0.504, P = 0.001).
In evaluating the correlation between the IPP and PVR indices, the mean PVR of patients before treatment for IPP subgroups of 1, 2, and 3 was 31.20 ± 36.78, 39.31 ± 40.38, and 69.14 ± 81.05, respectively. In other words, as the IPP increased, the patients' PVR also increased (P = 0.038). After the medical intervention, the mean PVR for the IPP subgroups was 21.68 ± 21.71, 27.00 ± 26.70, and 61.77 ± 59.89, respectively; again, indicating a significant difference between the three groups (P = 0.004). According to the Pearson correlation coefficient, there was a significant direct correlation between the IPP and PVR indices before (cc = 0.293, P = 0.029) and after the medical intervention (cc = 0.399, P = 0.002).
The mean PSA level for the IPP grades 1, 2, and 3 was 1.43 ± 0.80, 1.32 ± 0.68, and 2.79 ± 0.89, respectively. Those with an IPP greater than 10 mm had a significantly higher PSA level than the other two subgroups (P < 0.001). In this regard, there was a significant direct correlation between the IPP score and the PSA level (cc = 0.556, P < 0.001).
In evaluating the correlation between IPP value and Qmax index, the mean Qmax of patients before treatment for IPP grade 1, 2, and 3 subgroups was 16.21 ± 4.59, 12.25 ± 1.50, and 11.17 ± 3.09, respectively; which showed that with increasing IPP index, the Qmax of the patients decreased significantly (P = 0.002). Meanwhile, after the medical intervention, the mean Qmax of patients was 18.07 ± 5.17, 13.75 ± 2.99, and 9.83 ± 3.42, respectively, which was again indicating a significant difference between the three groups (P = 0.001). According to the Pearson correlation coefficient, there was a significant inverse correlation between the IPP score and the Qmax both before (cc = - 0.555, P < 0.001) and after the medical intervention (cc = - 0.695, P < 0.001).
Finally, the prevalence of the need for the surgical intervention in the IPP grades 1, 2, and 3 subgroups was 4%, 7.7%, and 36.4%, respectively, which showed a significant difference between the subgroups; so that the higher the IPP score, the more the need for surgery (P <0.007) (
Figure 2).
Frequency of surgical intervention need in IPP grade groups (P < 0.007).